Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events

European Journal of Clinical Investigation, Supplement

Volumn 35, Issue 1, 2005, Pages 21-26

  Drouet, L ^a   Bal Dit Sollier, C ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antifactor Xa; Factor Xa; Fondaparinux; Pathophysiology; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; META ANALYSIS; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOGENESIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 14844300139     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0960-135x.2005.01453.x     Document Type: Review

References (27)

1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr et al. Prevention of venous thromboembolism. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001;119 (Suppl.), 132S-175S.
2. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Onhop Scand 2000;71:47-50.
3. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
4. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-96.
5. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopaedic surgery using different composite efficacy endpoints. Chest 2004;126:501-8.
6. Cruickshank MK, Levine MN, Hirsh J, Turpie AG, Powers P, Jay R et al. An evaluation of impedance plethysmography and 1251-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989;62:830-4.
7. Hoek JA, Nurmohamed MT, ten Gate JW, Buller HR, Knipscheer HC, Hamelynck KJ et al. Thrombin-antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement. Thromb Haemost 1989;62:1050-2.
8. Ginsberg JS, Brill-Edwards P, Panju A, Patel A, McGinnis J, Smith F et al. Preoperative plasma levels of thrombin-antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Thromb Haemost 1995;74:602-5.
9. Cofrancesco E, Cortellaro M, Corradi A, Ravasi F, Bertocchi F. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Thromb Haemost 1997;77:267-9.
10. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35.
11. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119 (1 Suppl.):64S-94S.
12. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983;116:492-9.
13. Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15: 1-26.
14. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-25.
15. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
16. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304.
17. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-20.
18. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6.
19. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of four randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
20. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877-83.
21. Herault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-boun.d prothrombinase. J Pharmacol Exp Ther 1997;283:16-22.
22. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003;90:364-6.
23. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9-15.
24. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. J Thromb Haemost 2003;1:383-4.
25. Eriksson BI, Lassen MR, Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-42.
26. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000;102:2726-31.
27. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 2003;10:327-32.